Anticholinergic

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

Anticholinergic therapy caused significantly more dry mouth than onabotulinumtoxinA (46% vs 31%, P=0.02), though dry mouth was not a major cause of drug withdrawal.

Effect: adverse; 46% vs 31%

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months

OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting

Effect: adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months